An outpatient phase II study of subcutaneous interleukin-2 and interferon-alpha-2b in combination with intravenous vinblastine in metastatic renal cell cancer

Oncology
D PectasidesA Athanassiou

Abstract

A prospective phase II trial was carried out to define the activity of a low-dose subcutaneous regimen of interleukin-2 (IL-2) and interferon alpha-2b (IFN-alpha) in combination with intravenous administration of vinblastine (VLB) in patients with metastatic renal cell cancer (RCC). Thirty-one patients with advanced RCC who had received no prior biochemotherapy were treated with IL-2 4.5 MU x 2/24 h thrice weekly for 2 weeks, IFN-alpha 3 MU/24 h thrice weekly (alternating days) for 2 consecutive weeks and VLB 4 mg/m2 every 3 weeks. Patients were to have a 1-week rest period after each 2 weeks of therapy with cytokines. Treatment was repeated every 3 weeks. Maximum duration of treatment was 1 year. Treatment was administered on an outpatient basis. There were 4 complete (12.9%) and 8 partial responses (25.8%), with an overall response rate of 38.7%. The median duration of response was 6.5 months. Responses were seen in lung, lymph nodes, bones, liver and other tumor metastases. Toxicity was mild to moderate, consisting of fever, anorexia, malaise and nausea-vomiting in > 80% of patients. Hypotension and transient alopecia occurred in > 20% of patients. Liver enzyme elevation was frequently observed. Treatment-induced eosinophili...Continue Reading

Citations

May 20, 2004·European Urology·John S LamAllan J Pantuck
Nov 26, 1999·The Surgical Clinics of North America·A Jatoi, C L Loprinzi
Apr 14, 2000·European Journal of Cancer Care·D Porock, L Kristjanson
Nov 30, 2000·Journal of Advanced Nursing·S R Dirksen
Mar 2, 2011·Cancer Biotherapy & Radiopharmaceuticals·Robert O Dillman
Jul 31, 2013·Toxicological Sciences : an Official Journal of the Society of Toxicology·Sarah D LamoreMatthew F Peters
Jan 1, 2005·Current Opinion in Oncology·John W Eklund, Timothy M Kuzel
Aug 28, 2002·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Marios DecatrisKen O'Byrne
Dec 16, 1998·Lancet·N J Vogelzang, W M Stadler
Sep 7, 2014·BMC Urology·Anna M CzarneckaCezary Szczylik
Oct 26, 1999·Critical Reviews in Oncology/hematology·A Ravaud, M Debled
Mar 7, 2002·Critical Reviews in Oncology/hematology·C M L van Herpen, P H M De Mulder
Sep 29, 2000·Urologic Oncology·J Vuky, R J Motzer
Feb 26, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J AtzpodienUNKNOWN Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.